Menu Back toPopulation Diversity Considerations in Clinical Trials
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Population Diversity Considerations in Clinical Trials
Freda Cooner, PhD
- Director, Global Biostatistics
- Direction, Amgen, United States
To promote health equity and reduce disparities in racial and ethnic minorities, this session will discuss potential trial designs and statistical methods to increase the participation of minorities and/or diversity of populations in clinical trials.
Learning Objective : Discuss considerations and strategies in clinical trials' planning and conduct to enhance population diversity; Describe statistical challenges in clinical trial subgroup disparities; Identify potential trial designs and methodologies to mitigate disparity factors in the patient population.
Considerations on the Use of Analytics and Technology to Enhance Diversity in Clinical Trials
Demissie Alemayehu, PhD
- Vice President, Biostatistics
- Pfizer Inc, United States
Disparities by Demographic Subgroups in Clinical Trials Submitted to the FDA
Laura Fernandes, PhD
- United States
Ruthie Davi, PhD, MS
- Vice President, Data Science and Statistician
- Medidata, a Dassault Systèmes company, United States